The RSI Oscillator for HUMA moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 38 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 57 cases where HUMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for HUMA just turned positive on October 21, 2026. Looking at past instances where HUMA's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +1.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUMA advanced for three days, in 196 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
HUMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUMA as a result. In 82 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for HUMA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.671) is normal, around the industry mean (2.973). P/E Ratio (-0.794) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (52.083) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. HUMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Aroon Indicator for PROK entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator formed such a pattern. In 157 of the 180 cases the stock moved lower. This puts the odds of a downward move at 87%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PROK as a result. In 73 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
PROK moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PROK crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PROK's RSI Oscillator exited the oversold zone, 27 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROK advanced for three days, in 200 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PROK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.338) is normal, around the industry mean (2.973). P/E Ratio (-2.600) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. PROK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
HUMA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 89 | |
P/E GROWTH RATING 1..100 | 14 | |
SEASONALITY SCORE 1..100 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| HUMA | PROK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 73% |
| MACD ODDS (%) | 1 day ago 77% | N/A |
| TrendWeek ODDS (%) | 1 day ago 89% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 80% |
| Advances ODDS (%) | 1 day ago 81% | 3 days ago 79% |
| Declines ODDS (%) | 4 days ago 89% | 7 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 87% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HUMA’s FA Score shows that 1 FA rating(s) are green while PROK’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HUMA’s TA Score shows that 5 TA indicator(s) are bullish while PROK’s TA Score has 4 bullish TA indicator(s).
HUMA (@Biotechnology) experienced а -6.01% price change this week, while PROK (@Biotechnology) price change was -1.72% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
HUMA is expected to report earnings on Nov 11, 2026.
PROK is expected to report earnings on Nov 09, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, HUMA has been loosely correlated with CRSP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if HUMA jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To HUMA | 1D Price Change % | ||
|---|---|---|---|---|
| HUMA | 100% | +0.46% | ||
| CRSP - HUMA | 40% Loosely correlated | -1.01% | ||
| EDIT - HUMA | 38% Loosely correlated | -0.80% | ||
| RXRX - HUMA | 37% Loosely correlated | -1.65% | ||
| BEAM - HUMA | 36% Loosely correlated | -1.13% | ||
| RCKT - HUMA | 35% Loosely correlated | +5.00% | ||
More | ||||
A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RXRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To PROK | 1D Price Change % | ||
|---|---|---|---|---|
| PROK | 100% | -0.69% | ||
| RXRX - PROK | 50% Loosely correlated | -1.65% | ||
| SANA - PROK | 47% Loosely correlated | +0.85% | ||
| NKTX - PROK | 47% Loosely correlated | -0.57% | ||
| EDIT - PROK | 44% Loosely correlated | -0.80% | ||
| IMTX - PROK | 43% Loosely correlated | -1.95% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| THTA | 15.60 | -0.13 | -0.83% |
| SoFi Enhanced Yield ETF (THTA) | |||
| DFAI | 41.41 | -0.38 | -0.91% |
| Dimensional International Core Equity Market ETF (DFAI) | |||
| SEF | 29.82 | -0.34 | -1.13% |
| ProShares Short Financials (SEF) | |||
| UFOX | 77.44 | -3.44 | -4.26% |
| Defiance Space and Connective Tech ETF (UFOX) | |||
| SHOC | 95.20 | -6.36 | -6.26% |
| Strive U.S. Semiconductor ETF (SHOC) | |||